Targeting CDK7 reverses tamoxifen resistance through regulating stemness in ER+ breast cancer-Reference-Cited by-同舟云学术

Targeting CDK7 reverses tamoxifen resistance through regulating stemness in ER+ breast cancer

Published:2022-01-09 Issue:2 Volume:74 Page:366-378
ISSN:1734-1140
Container-title:Pharmacological Reports
language:en
Short-container-title:Pharmacol. Rep

Author:

Attia Yasmin M.,Salama Salama A.^ORCID,Shouman Samia A.,Ivan Cristina,Elsayed Abdelrahman M.,Amero Paola,Rodriguez-Aguayo Cristian,Lopez-Berestein Gabriel

Funder

national institutes of health

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s43440-021-00346-9.pdf

Reference56 articles.

1. Azodi MZ, Ardestani H, Dolat E, Mousavi M, Fayazfar S, Shadloo A. Breast cancer: genetics, risk factors, molecular pathology and treatment. Arch Adv Biosci. 2013;4(1):112–20.

2. Masoud V, Pagès G. Targeted therapies in breast cancer: new challenges to fight against resistance. World J Clin Oncol. 2017;8(2):120. https://doi.org/10.5306/wjco.v8.i2.120.

3. Polyak K. Heterogeneity in breast cancer. J Clin Investig. 2011;121(10):3786–8. https://doi.org/10.1172/JCI60534.3786.

4. Stingl J, Caldas C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer. 2007;7(10):791–9. https://doi.org/10.1038/nrc2212.

5. Miller TW. Endocrine resistance: what do we know? Am Soc Clin Oncol Educ Book. 2013;33(1):e37-42.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CDK7 in breast cancer: mechanisms of action and therapeutic potential;Cell Communication and Signaling;2024-04-11

2. Tamoxifen Modulates the Immune Landscape of the Tumour Microenvironment: The Paired Siglec-5/14 Checkpoint in Anti-Tumour Immunity in an In Vitro Model of Breast Cancer;International Journal of Molecular Sciences;2023-03-14

3. Targeting CDK7 in oncology: The avenue forward;Pharmacology & Therapeutics;2022-12